SAE Media Group Pharma

🚀 What a whirlwind of an event! 🌪️ We heard insightful information, shared expertise, and formed important relationships with networking galore! 🤝 We would like to take this opportunity to thank all of our speakers and sponsors for their ongoing support in this event; Martin Akerman, Richard Geary, Sudhir Agrawal D.Phil, FRSC, Sandy Hinckley, Kinkini Roy, PhD, Zimeng Wang, Jason Zhang, Jay Sarkar, Derek O'Hagan, Hetal Patel Ph.D., Kevin Kim, Pushkar Saralkar, Sourav Choudhury, Steve Pascolo, Yue Hui, Zdravka Medarova, TriLink BioTechnologies, part of Maravai LifeSciences, ChemGenes   Looking ahead, don’t miss out on RNA Therapeutics UK in February 2024! 🌟 We have a stellar line-up including: 🌟 Christalyn Rhodes, Ph.D., AVP - Genetic Medicine - External Partnerships and Academic Collaborations, Eli Lilly 🌟 Heinrich Haas, Technology Officer, NeoVac 🌟 Ka-Wai Wan, MHRA Pharmaceutical Assessor, MHRA Find out more today! 👉 www.therapeutics-rna.com #RNATherapeutics #SAERNA #Conference #mRNA #Innovation #Biotech #Pharmaceuticals #TriLink #ChemGenes #RNATx2025

🌟 Next up we welcomed Derek O'Hagan, Senior Advisor R&D at GSK, who presented on ‘The Role of Adjuvants in Vaccine Development.’ Derek provided a comprehensive review of the mechanisms and science behind adjuvants, discussing how they enhance immune responses and their potential to improve the performance of RNA vaccines. 💉✨ He also shared insights into the future outlook, exploring what the next generation of adjuvants might look like. We look forward to continued discussions on this vital topic! #mRNA #Vaccines #Adjuvants #Immunology #Innovation #Biotech #GSK

🌟 Pushkar Saralkar, Senior Scientist at Pfizer, delivered an insightful presentation on ‘Formulation Considerations for mRNA-Lipid Nanoparticles: Vaccines and Beyond.’ Pushkar Explored: - The formulation aspects of lipid nanoparticles contributing to mRNA vaccine success. - Challenges in formulation and process parameters during product development. - Key considerations for designing mRNA-lipid nanoparticle drug products, whether as therapeutics or vaccines. 💉✨ Following Pushkar, Hetal Patel Ph.D., Senior Principal Scientist/Group Leader at Pfizer, shared valuable insights on the practical application of platform analytical procedures in late-stage development of mRNA. Hetal covered: - Leveraging guidance from ICH Q2 (R2) and ICH Q14. - The importance of using historical data to reduce redundancy and ensure rapid commercial readiness. 📊 Thank you to both speakers for their contributions, we enjoyed even more engaging discussions during our networking lunch! 🍽️ #mRNA #Vaccines #LipidNanoparticles #Pharmaceuticals #Innovation #Biotech #Pfizer #Networking

🌟 Another expert we were delighted to welcome was Yue Hui, Scientist at Moderna who presented on ‘mRNA Process Science and Engineering: First Steps Towards a Novel Modality.’ Yue explored the potential of mRNA as a groundbreaking modality for vaccines and therapeutics, diving into the fundamentals of LNP assembly and the crucial role of fluid dynamics. She also shared an insightful case study on the CMV vaccine, highlighting the practical applications of this innovative technology. 💉 We were intrigued by these valuable contributions and inspired by the important points made, and hope you were too! 🙌 #mRNA #Vaccines #Therapeutics #LNP #Innovation #Biotech #Moderna #ProcessScience

🌟What an incredible first day! After engaging debates on progressive RNA-based solutions and expert presentations showcasing innovative case studies, we’re excited to dive into day 2! Here are some highlights from day 1: Martin Akerman, CTO of Envisagenics introduced SpliceCore, an AI-driven platform that identifies novel therapeutic targets for neurodegenerative diseases like ALS by leveraging alternative splicing. Zimeng Wang from AstraZeneca shared insights on the dual role of PEG-lipids in lipid nanoparticles (LNPs). Richard Geary of Ionis Pharmaceuticals, Inc. spoke about antisense therapy, providing fresh insights into the effects of antisense technology on neurodegenerative and neurodevelopmental disorders. Dr. Geary highlighted nusinersen and tofersen as examples of antisense therapies in action. Sudhir Agrawal D.Phil, FRSC Agrawal, founder and president of ARNAY Sciences Sciences, highlighted 'Cyclic Structured Oligonucleotides for RNA Therapeutics' at the RNA Therapeutics USA Conference. Jason Zhang, Co-Founder and CEO of Zipcode Bio, discussed the use of advanced machine learning for RNA therapy development, the SHARP platform for mRNA delivery, and their innovative immunology pipeline. Kinkini Roy, PhD Roy, Associate Director at Aviceda Therapeutics Therapeutics, highlighted the importance of targeted delivery in enhancing therapeutic efficacy while comparing active and passive targeting methods. Jay Sarkar from Stanford University School of Medicine presented on drug routers and network paradigms for drug delivery, focusing on router-induced networks and in vivo studies. To wrap up the day, we enjoyed a fantastic networking event, allowing attendees to deepen connections and share experiences. Thank you to all of our day one speakers: Martin Akerman Richard Geary Sudhir Agrawal D.Phil, FRSC Sandy Hinckley Kinkini Roy, PhD Zimeng Wang Jason Zhang Jay Sarkar Now, it’s time for round 2—see you soon! 🚀 #RNA #DrugDelivery #Innovation #Biotech #Networking #ALS #Therapeutics #MachineLearning #LipidNanoparticles #mRNA #Envisagenics #ZipcodeBio #AvicedaTherapeutics #StanfordUniversity

🌟 Our Chair, and first speaker of the day, Sourav Choudhury, Head of AAV Technologies at Sanofi delved into the use of viral delivery platforms to enhance therapeutic delivery and the exciting potential of capsid development. 🎤 He emphasized how leveraging AI can deepen our understanding of capsid functioning and foster innovation in this field. Sourav also highlighted examples of machine learning-guided capsid development, showcasing the transformative impact of technology on changes to the industry, which made for compelling listening! 🔍✨ #RNATherapeutics #GeneTherapy #AAV #MachineLearning #Innovation #Biotech #ViralDelivery

🌟 As a Senior Scientist, Zimeng Wang, of AstraZeneca, explained his insights on the dual role of PEG-lipids in lipid nanoparticles (LNPs). He covered: - Role of PEG-lipids: The dual role of PEG-lipids in LNPs, essential for stability but potentially hindering efficacy. - Innovative Solution: PEG copolymer coatings to maintain particle size during storage while allowing rapid shedding after administration, enhancing in vivo efficacy. - Study Focus: Optimized fabrication and LNP composition, particularly with poloxamer 407 (P407) coated LNPs. - In Vivo Results: P407 improved mRNA distribution to the spleen and lungs compared to traditional PEG-lipid LNPs, though luciferase protein levels were lower, indicating further optimization is needed. - In Vitro Improvements: Increased phospholipid ratios in optimized LNPs significantly boosted efficacy. Attendees engaged in lively discussions about advancements in mRNA delivery! 🚀 #LipidNanoparticles #Biotechnology #mRNA #AstraZeneca #Innovation #SAERNA

🌟 It was great to hear from Sandy Hinckley, VP and Head of Discovery at QurAlis Corporation who shared exciting advancements in the development of splice-switching oligonucleotides for CNS diseases. In this session the signification of pre-mRNA mis-splicing in CNS conditions and how splice switching antisense oligonucleotides (ASOs) offer a powerful approach to correct these errors effectively. QurAlis Corporation’s innovative FlexASO™ platform allows them to design splice switching ASOs with improved potency, safety, and biodistribution. Sandy discussed the platform in the context of their discovery plans. 💡 #Neurodegeneration #ASOs #Biotechnology #QurAlis #Innovation #SAERNA

As Founder and President of ARNAY Sciences, Sudhir Agrawal D.Phil, FRSC, highlights 'Cyclic Structured Oligonucleotides for RNA Therapeutics' at the RNA Therapeutics USA Conference. Key Insights: 🔵 The crucial role of sequence and chemistry in enhancing oligonucleotide properties. 🔵 Early efforts focused on improving nuclease stability and affinity, leading to gapmer antisense and modified RNA for splice modulation. 🔵 Discovering Pattern Recognition Receptors (PRRs) to deepen understanding of immune activation, while Structure-Activity Relationship (SAR) studies helped minimize immune responses. Today, they’re using these insights to develop next-generation antisense therapies with transient cyclic structures for efficient delivery, boosting potency and specificity. We were thrilled to explore the future of oligonucleotide and RNA therapies! 🌟 #Biotechnology #Oligonucleotides #DrugDevelopment #Immunology #ARNAYSciences #SAERNA

Recently, Recursion and Exscientia joined forces to revolutionise the drug discovery landscape! By merging Recursion's innovative biology exploration with Exscientia's cutting-edge precision chemistry, they're launching a state-of-the-art end-to-end drug discovery platform. This powerful collaboration is set to accelerate the delivery of better treatments—faster and at lower costs. Want to dive deeper into this ground-breaking partnership? Join us at the AI in Drug Discovery Conference in London on March 10-11, where Maureen Makes, VP of Engineering at Recursion alongside Peter Clark, PhD, VP, Computational Drug Design, Novo Nordisk will be sharing exclusive insights. Early bird tickets are available for a limited time—grab yours now and save £400! Don’t miss this opportunity to be at the forefront of innovation in drug discovery. Register today➡https://ow.ly/XPCK50TRzPL Sponsor: Schrödinger #AIDrugDis #SAEMGPharma #GenerativeAI #TargetID #pharmaceuticals